new molecular entities in our late-stage pipeline 2 new molecular entities under review Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (...
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca View announcement Latest presentations Q1 2025 results View latest results and presentations We have 194 projects in our pipeline View pipeline Learn about our cell therapy ambition ...
View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres Sustainability at AstraZeneca Corporate Press Release Enhertu followed by THP before surgery showed statistically significant and clinically mea...
View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres Sustainability at AstraZeneca Corporate Press Release Imfinzi approved in the US as first and only immunotherapy regimen for patients with ...
Discover how we champion inclusion and diversity at AstraZeneca We have 199 projects in our pipeline View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres ...
Discover how we champion inclusion and diversity at AstraZeneca We have 199 projects in our pipeline View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres ...
View pipeline Learn about our cell therapy ambition The Discovery Centre in Cambridge (UK) is one of our global science centres Explore all our science centres Sustainability at AstraZeneca Corporate Press Release Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR...
Oncology is one of the company's core therapy areas and accelerating the development of a number of new molecular entities in its pipeline is a strategic priority.Adeline Siew, PhDPharmaceutical Technology
and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients arou...
AstraZeneca aims to create a “2.0” cancer pipeline and is giving ESMO-goers a peek at data for 3 of its bispecific antibody candidates.